Assessing Candidate Serum Biomarkers for Alzheimer's Disease: A Longitudinal Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Because of the growing impact of late onset cognitive loss, considerable effort has been directed toward the development of improved diagnostic techniques for Alzheimer's disease (AD) that may pave the way for earlier (and more effective) therapeutic efforts. Serum-based biomarkers are the least expensive and invasive modality for screening and routine monitoring. We systematically reviewed the literature to assemble a list of serum biomarkers relevant to AD. In parallel, we conducted a proteomic LC-MS/MS analysis of serum collected from neurologically normal subjects and subjects with mild cognitive impairment (MCI) and early AD (n = 6 in all). Complement C3 and alpha-2-macroglobulin were identified from both the literature review and our proteomic screen for further validation. For these two candidates, ELISA was performed on serum collected from a small independent cohort of subjects for longitudinal analysis. Serum was serially collected from neurologically normal subjects (n = 5) and subjects with MCI who were subsequently followed for a period of two years (n = 5) and regrouped into stable MCI and progressive MCI or AD (n = 6). The ability of each marker to predict which subjects with MCI would progress to dementia and which would remain cognitively stable was assessed. Patients with probable cerebral amyloid angiopathy were also identified (n = 3). This preliminary analysis tested the most-promising serum protein biomarkers for AD and we concluded that none are yet ready for use in the clinical diagnosis and management of dementia. However, a more thorough assessment in longitudinal studies with higher statistical power is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
Serial Susceptibility Weighted MRI Measures Brain Iron and Microbleeds in Dementia
Kirsch, W., McAuley, G., Holshouser, B., Petersen, F., Ayaz, M., Vinters, H. V., Dickson, C., Haacke, E. M., Britt III, W., Larsen, J., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1073 · Cited by 139
Self-citationPlasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., Schiavon, R., & Corbo, R. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00889-1 · Cited by 83
Cited by
Shen, X.-N., Niu, L.-D., Wang, Y.-J., Cao, X.-P., Liu, Q., Tan, L., Zhang, C., & Yu, J.-T. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319148 · Cited by 388
Complement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
“A few plasma markers have been described but are untested in preclinical disease and likely unsuitable for early diagnosis [75, 76].”
BackgroundCastillo, E., Leon, J., Mazzei, G., Abolhassani, N., Haruyama, N., Saito, T., Saido, T., Hokama, M., Iwaki, T., Ohara, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17999-3 · Cited by 158
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
The role of neuroinflammation in cerebral amyloid angiopathy
van den Brink, H., Voigt, S., Kozberg, M., & van Etten, E. S. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105466 · Cited by 39
Metadata
- Authors
- Zabel, M., Schrag, M., Mueller, C., Zhou, W., Crofton, A., Petersen, F., Dickson, A., & Kirsch, W. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-05-21
- Volume
- 30
- Issue
- 2
- Pages
- 311-321
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1483322061
- Cited by
- 41
- References
- 3
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing Candidate Serum Biomarkers for Alzheimer's Disease: A Longitudinal Study. https://app.cochat.ai/papers/10.3233/jad-2012-112012
- The paper
- Zabel, M., Schrag, M., Mueller, C., Zhou, W., Crofton, A., Petersen, F., Dickson, A., & Kirsch, W. M. (2012). Assessing Candidate Serum Biomarkers for Alzheimer's Disease: A Longitudinal Study. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2012-112012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.